
EC approves BMS’ perioperative Opdivo and chemo for NSCLC
The European Commission (EC) has granted approval to Bristol Myers Squibb’s (BMS) perioperative regimen of neoadjuvant Opdivo (nivolumab), combined with chemotherapy and followed by adjuvant Opdivo and surgery, for treating resectable non-small cell lung …